Generalized Anxiety Disorder
Conditions
Keywords
CES
Brief summary
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.
Detailed description
This study examines (1) the efficacy of CES with the Alpha-Stim AID ® for the treatment of GAD in young adults (18-21 years of age) in a double-blind, sham-controlled parallel group single-site clinical trial of 130 participants. Participants will be randomized into receiving either active CES (at least 200uA, up to 500uA at 0.5Hz, 60 minutes daily for six weeks) or sham CES with the Alpha-Stim AID ® device at-home. Clinical assessments of anxiety symptoms are performed at Screening (for eligibility), Baseline, Follow-Up 1 (at completion of intervention, 6 weeks after initial stimulation), and Follow-Up 2 (12 weeks after initial stimulation). Additional assessments of depression symptoms and quality of life are included. Resting-state EEG will be collected at baseline and Follow-Up 1 (in up to 60 participants) for exploratory investigation of mechanism of action.
Interventions
DEVICEAt-Home Stimulation
The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions.
Sponsors
Electromedical Products International, Inc.
University of North Carolina, Chapel Hill
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Capable of signing informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study including refraining from changes to treatment unless medically indicated and communicated to the study team. * Aged 18 - 21 at time of screening visit. * Diagnosis of generalized anxiety disorder (GAD). * At least mild-to-moderate symptom severity, as indicated by scores of 15 or higher on the clinician-administered HAM-A at the screening visit. * Concurrent psychiatric medications are allowed. Participants will be required to maintain a sable dose of medications, or remain medication free, for 2 weeks prior to the screening visit, except for antidepressants for which the period of stable dose is 4 weeks prior to screening visit. Concurrent psychotherapy is allowed. * People of reproductive potential must be willing to use effective contraception (evidence-based hormonal or barrier methods) for at least 1 month prior to the screening visit and agree to use such a method during study participation.
Exclusion criteria
Time-frames are determined relative to the screening visit. * Current (any) or previous (\> 7 stimulation sessions in last 6 weeks) use of a CES device. * Inability to tolerate the required minimum stimulation amplitude (200 uA) during the initial device training at the baseline visit. * Experimental or clinical brain stimulation such as deep brain stimulation or transcranial magnetic stimulation for any indication (current or within 60 days prior to screening visit). * Implanted medical device that uses electricity anywhere in the body. * Diagnosis (based on MINI) of bipolar I or II (past or current), moderate or severe alcohol use disorder (within 12 months prior to screening visit), moderate or severe (non-alcohol) substance use disorder (within 12 months prior to screening visit), psychotic disorder (current or lifetime), major depressive disorder with psychotic features, bipolar I with psychotic features, anorexia nervosa. * Epilepsy (current or history). History of febrile childhood seizures and non-epileptic seizures are allowed. * Pregnant or breast-feeding. * Enrollment in clinical trial for any condition (current or within 60 days prior to screening visit). * Hospitalization for any reason (current or past 2 weeks). * Self-harming behaviors (current or within two years prior to screening visit). * Higher than low suicide risk on the Columbia Suicide Severity Rating Scale (C-SSRS). * Known cardiac abnormality or clinically significant heart disease. * Anything that would make participation in the study unsafe or medically unadvisable in the assessment of a study clinician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Anxiety Rating Scale (HAM-A) change | 42 days | Change in HAM-A between six-week follow-up (FU1) and baseline (D1); minimum value is 0, maximum value is 56. Higher scores indicate worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Anxiety Rating Scale (HAM-A) change | 84 days | Change in HAM-A between twelve-week follow-up (FU2) and D1; minimum value is 0, maximum value is 56. Higher scores indicate worse outcome. |
| Beck Anxiety Inventory (BAI) Change | 42 days | Change in BAI between FU1 and D1; minimum value is 0, maximum value is 63. Higher scores indicate worse outcome. |
| Generalized-Anxiety Disorder 7-item (GAD-7) Change | 42 days | Change in GAD-7 between FU1 and D1; minimum value is 0, maximum value is 21. Higher scores indicate worse outcome. |
| Response/Remission of anxiety | 42 days | Response/remission rates based on HAM-A scores from FU1 versus baseline D1 |
| Change in Clinical Global Impression Scale (CGI) | 42 days | Change in CGI from FU1 to D1; CGI scale contains two scoring components, 1) Severity of Illness (0-7) and 2) Global Improvement (0-7). Higher scores in component 1 indicate worse symptoms while higher numbers in component 2 indicate worse clinical outcomes. |
| Change in Quality of Life Enjoyment and Satisfaction Questionnaire, short form (Q-LES-Q-SF) | 42 days | Change in Q-LES-Q-SF from FU1 to D1; minimum value is 14, maximum value is 70. Higher scores indicate better outcome. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSamantha Meltzer-Brody, MD
University of North Carolina, Chapel Hill
Outcome results
None listed